Da Volterra is looking forward to attending ECCMID April 21st-24th in Madrid where we will present posters on DAV132 and on our prospective study, ANTICIPATE, in partnership with our academic colleagues and IMI.
To see our new data for DAV132, visit our poster “Dose-effect and safety of DAV132, an activated charcoal based product, when given with oral moxifloxacin on free moxifloxacin fecal concentrations and intestinal microbiota diversity: A randomized controlled trial (RCT) in 144 healthy volunteers (HVs)”during the “Microbiome and beyond” poster session at 12:30-13:30 on April 22, 2018.
In order to prevent devastating Clostridium difficile infections and combat antibiotic resistance, Da Volterra is advancing clinical development for DAV132 which aims to prevent CDIs by protection of the intestinal microbiota. DAV132 has demonstrated excellent safety in four Phase 1 clinical trials and is entering Phase 2 in early 2018. To learn more about DAV132 please follow the link.